Income statement
CAD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -38K | -68K | -64K | -15K | 0 |
| Operating Income | -6M | -2M | -1M | -3M | -237K |
| EBITDA | -6M | -2M | -1M | -3M | -237K |
| Net Income | -6M | -2M | -1M | -3M | -237K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.094
+10.59% today
1Y Change
-45.90%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Unidoc Health Corp. (UDOCF) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.09 and down 45.9% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +8.3%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +8.3%, free cash flow -1267.2% with operating margin -409.0% and ROIC -2986.5%. Valuation already assumes a fairly strong business story at price/sales 8.7. Stock Foundry combines UDOCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UDOCF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UDOCF Max Drawdown
-63.68%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UDOCF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$237.3K
+92.1% YoY
Free Cash Flow
$17.3K
+100.7% YoY
Revenue Growth
+0.0%
EPS Growth
+8.3%
Gross Margin
17.7%
Net Margin
-447.2%
Income statement
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -38K | -68K | -64K | -15K | 0 |
| Operating Income | -6M | -2M | -1M | -3M | -237K |
| EBITDA | -6M | -2M | -1M | -3M | -237K |
| Net Income | -6M | -2M | -1M | -3M | -237K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 1M | 399K | 51K | 854K | 282K |
| Total Assets | 3M | 517K | 320K | 1M | 288K |
| Total Liabilities | 2M | 2M | 1M | 722K | 425K |
| Shareholder Equity | 665K | -2M | -901K | 456K | -137K |
| Total Debt | 69K | 75K | 95K | 79K | 200K |
| Net Debt | -1M | -324K | 43K | -775K | -82K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17K
+100.7% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
17K
+100.7% YoY
Key ratios
Gross Margin
17.7%
Operating Margin
-409.0%
Net Margin
-447.2%
ROE
6239.2%
Debt / Equity
-1.34x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.